929 / 1851
Prospective Study
- primary endpoint: proportion of patients with an abscopal response
- in chemotherapy and hormone therapy refractory metastatic patients
- in combination with GM-CSF: DC stimulation
|
|
929 / 1851
Prospective Study
- primary endpoint: proportion of patients with an abscopal response
- in chemotherapy and hormone therapy refractory metastatic patients
- in combination with GM-CSF: DC stimulation